Case number 1:22-cv-01312
Galderma Laboratories, L.P. et al v. Alembic Pharmaceuticals Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 3, 2023 | 54 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' First Set of Requests for Production of Documents and Things (No. 1) filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 07/03/2023) (3) |
| Jun 16, 2023 | 53 | SO ORDERED, regarding D.I. 51 STIPULATION TO EXTEND TIME for Certain Claim Construction Deadlines to Various Dates (Claim Construction Opening Brief due by 7/7/2023., Claim Construction Answering Brief due by 7/21/2023., Claim Construction Reply Brief due by 8/4/2023., Claim Construction Surreply Brief due by 8/18/2023., Joint Claim Construction Brief due by 8/23/2023.) Signed by Judge Stephanos Bibas on 6/16/2023. (apk) (Entered: 06/16/2023) (0) |
| Jun 15, 2023 | 52 | NOTICE OF SERVICE of Defendants' Responses And Objections To Plaintiffs' First Set Of Requests For Production Of Documents And Things (Nos. 1-119) filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Palapura, Bindu) (Entered: 06/15/2023) (2) |
| Jun 15, 2023 | 51 | STIPULATION TO EXTEND TIME for Certain Claim Construction Deadlines to Various Dates - filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 06/15/2023) (2) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibits 13-16) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibits 7-12) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibits 5-6) (13) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibit 4 - Part 6) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibit 4 - Part 5) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibit 4 - Part 4) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibit 4 - Part 3) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibit 4 - Part 2) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibit 4 - Part 1) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Exhibits 1-3) (30) |
| Jun 12, 2023 | 50 | Joint APPENDIX re 49 Claim Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibits 1-3, # 2 Exhibit 4 - Part 1, # 3 Exhibit 4 - Part 2, # 4 Exhibit 4 - Part 3, # 5 Exhibit 4 - Part 4, # 6 Exhibit 4 - Part 5, # 7 Exhibit 4 - Part 6, # 8 Exhibits 5-6, # 9 Exhibits 7-12, # 10 Exhibits 13-16)(Tigan, Jeremy) (Entered: 06/12/2023) (Main Document) (1) |
| Jun 12, 2023 | 49 | CLAIM Construction Chart by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 06/12/2023) (12) |
| Jun 12, 2023 | 48 | SO ORDERED, regarding D.I. 47 STIPULATION TO EXTEND TIME for the parties to file a joint claim construction chart to June 12, 2023 (Joint Claim Construction Chart due by 6/12/2023.) Signed by Judge Stephanos Bibas on 6/12/2023. (apk) (Entered: 06/12/2023) (0) |
| Jun 9, 2023 | 47 | STIPULATION TO EXTEND TIME for the parties to file a joint claim construction chart to June 12, 2023 - filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 06/09/2023) (1) |
| Jun 5, 2023 | 46 | NOTICE OF SERVICE of Defendants' First Set Of Requests For The Production Of Documents And Things (No. 1) To Plaintiffs, and Defendants' Preliminary Identification Of Claim Terms And Proposed Constructions filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Brown, Andrew) (Entered: 06/05/2023) (2) |
| Jun 2, 2023 | 45 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms for Construction filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 06/02/2023) (3) |
| Jun 1, 2023 | 44 | NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Palapura, Bindu) (Entered: 06/01/2023) (2) |
| May 16, 2023 | 43 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Claim Chart filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 05/16/2023) (3) |
| May 10, 2023 | 42 | STIPULATION TO EXTEND TIME for: (1) Plaintiffs Galderma Laboratories, L.P. and TCD Royalty Sub LP to serve their initial infringement contentions to Tuesday, May 16, 2023; and (2) Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc. to serve their invalidity contentions to May 31, 2023 - filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 05/10/2023) (2) |
| May 9, 2023 | 41 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for the Production of Documents and Things filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 05/09/2023) (3) |
| Apr 14, 2023 | 40 | NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Identifying Defendants' Accused Products and Plaintiffs' Asserted Patents filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 6, 2023 | 39 | NOTICE OF SERVICE of Defendants' Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Moore, David) (Entered: 04/06/2023) (2) |
| Mar 27, 2023 | 38 | PROPOSED ORDER -- [Proposed] Stipulated Order Regarding Discovery, Including Discovery of Electronically Stored Information ("ESI") -- by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 03/27/2023) (10) |
| Mar 27, 2023 | 37 | PROPOSED ORDER -- [Proposed] Stipulated Protective Order -- by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 03/27/2023) (19) |
| Mar 24, 2023 | 36 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Palapura, Bindu) (Entered: 03/24/2023) (2) |
| Mar 24, 2023 | 35 | NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery, Including Discovery of Electronically Stored Information ("ESI") filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 03/24/2023) (3) |
| Mar 17, 2023 | 33 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Rule 26(a)(1) Initial Disclosures filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Palapura, Bindu) (Entered: 03/17/2023) (2) |
| Mar 17, 2023 | 34 | NOTICE OF SERVICE of Plaintiffs' Rule 26(a)(1) Initial Disclosures filed by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 03/17/2023) (3) |
| Mar 13, 2023 | 32 | SCHEDULING ORDER: Joinder of Parties due by 9/1/2023. Amended Pleadings due by 9/1/2023. Discovery due by 11/3/2023. Opening Expert Reports due by 12/8/2023. Rebuttal Expert Reports due by 1/12/2024. Expert Discovery due by 2/9/2024. Status Report due by 11/10/2023. Claim Construction Opening Brief due by 6/23/2023. Claim Construction Answering Brief due by 7/7/2023. Claim Construction Reply Brief due by 7/21/2023. Claim Construction Surreply Brief due by 8/4/2023. Joint Claim Construction Brief due by 8/9/2023. Proposed Pretrial Order due by 4/19/2024. Signed by Judge Stephanos Bibas on 03/13/2023. (smg) (Entered: 03/13/2023) (14) |
| Mar 10, 2023 | 31 | Joint PROPOSED ORDER -- Proposed Scheduling Order -- (with disputed provisions) re 30 Oral Order, by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 03/10/2023) (17) |
| Mar 6, 2023 | 30 | ORAL ORDER, I ORDER the parties to submit a proposed scheduling order by March 10, 2023, at 5 p.m. eastern time. If the parties cannot agree, each party shall submit a proposed scheduling order, including any potential waivers and stipulations. Signed by Judge Stephanos Bibas on 3/6/2023. (twk) (Entered: 03/06/2023) (0) |
| Mar 3, 2023 | 29 | Letter to The Honorable Stephanos Bibas from Jeremy A. Tigan regarding Joint Status Report - re 26 Oral Order,. (Tigan, Jeremy) (Entered: 03/03/2023) (3) |
| Feb 28, 2023 | 28 | SO ORDERED, re 27 STIPULATION TO EXTEND TIME to submit the joint status report required by the Court's February 21, 2023 Oral Order (D.I. 26 ) to March 3, 2023. Ordered by Judge Stephanos Bibas on 2/28/2023. (twk) (Entered: 02/28/2023) (0) |
| Feb 27, 2023 | 27 | STIPULATION TO EXTEND TIME to submit the joint status report required by the Court's February 21, 2023 Oral Order (D.I. 26) to March 3, 2023 - filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Palapura, Bindu) (Entered: 02/27/2023) (2) |
| Feb 21, 2023 | 26 | ORAL ORDER: I ORDER the parties to confer and submit a joint status report, not to exceed three single-spaced pages, by February 28, 2023, at 5 p.m. eastern time. The report shall discuss Galderma Laboratories L.P. v. Lupin Inc., 1:21-cv-01710-SB, as well as the need for a scheduling conference and scheduling order. Ordered by Judge Stephanos Bibas on 02/21/2023. Associated Cases: 1:22-cv-00724-SB, 1:22-cv-01166-SB, 1:22-cv-01312-SB(smg) (Entered: 02/21/2023) (0) |
| Feb 14, 2023 | 25 | MOTION for Pro Hac Vice Appearance of Attorney Sasha S. Rao - filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Brown, Andrew) (Entered: 02/14/2023) (3) |
| Feb 9, 2023 | 24 | SO ORDERED, re 23 MOTION for Pro Hac Vice Appearance of Attorneys Gerald J. Flattmann, Jr. and Andrew J. Cochran. Signed by Judge Stephanos Bibas on 2/9/2023. (twk) (Entered: 02/09/2023) (0) |
| Feb 8, 2023 | 23 | MOTION for Pro Hac Vice Appearance of Attorney Gerald J. Flattmann, Jr. and Andrew J. Cochran - filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 02/08/2023) (5) |
| Feb 3, 2023 | 22 | NOTICE requesting Clerk to remove Evan D. Diamond, Vanessa Y. Yen, and the law firm of King & Spalding LLP as co-counsel.. (Tigan, Jeremy) (Entered: 02/03/2023) (2) |
| Feb 2, 2023 | 21 | NOTICE requesting Clerk to remove Robert Stout as co-counsel. Reason for request: no longer with the firm of Sterne Kessler Goldstein Fox PLLC. (Palapura, Bindu) (Entered: 02/02/2023) (1) |
| Jan 5, 2023 | 20 | NOTICE of Change of Firm Affiliation by Galderma Laboratories, L.P., TCD Royalty Sub LP (Blumenfeld, Jack) (Entered: 01/05/2023) (3) |
| Dec 21, 2022 | 19 | ANSWER to 16 Answer to Complaint, Counterclaim by Galderma Laboratories, L.P., TCD Royalty Sub LP.(Tigan, Jeremy) (Entered: 12/21/2022) (13) |
| Dec 7, 2022 | 18 | REDACTED VERSION of 16 Answer to Complaint, Counterclaim by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Attachments: # 1 Exhibit 1-7)(Palapura, Bindu) (Entered: 12/07/2022) (Exhibit 1-7) (30) |
| Dec 7, 2022 | 18 | REDACTED VERSION of 16 Answer to Complaint, Counterclaim by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Attachments: # 1 Exhibit 1-7)(Palapura, Bindu) (Entered: 12/07/2022) (Main Document) (30) |
| Nov 30, 2022 | 17 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alembic Global Holdings SA for Alembic Pharmaceuticals Inc.; Corporate Parent none for Alembic Pharmaceuticals Limited filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Palapura, Bindu) (Entered: 11/30/2022) (2) |
| Nov 30, 2022 | 16 | [SEALED] ANSWER to 1 Complaint, , COUNTERCLAIM against Galderma Laboratories, L.P., TCD Royalty Sub LP by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Attachments: # 1 Exhibit 1-7)(Palapura, Bindu) (Entered: 11/30/2022) (0) |
| Nov 29, 2022 | 15 | SO ORDERED, regarding D.I. 14 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to November 30, 2022 filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Signed by Judge Stephanos Bibas on 11/29/2022. (apk) (Entered: 11/29/2022) (0) |
| Nov 28, 2022 | 14 | STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to November 30, 2022 - filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Moore, David) (Entered: 11/28/2022) (2) |
| Oct 24, 2022 | 13 | SO ORDERED, re 12 MOTION for Pro Hac Vice Appearance of Attorney Dennies Varughese, Paul A. Ainsworth, Davin B. Guinn and Robert Stout of Sterne Kessler Goldstein Fox PLLC filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Signed by Judge Stephanos Bibas on 10/24/2022. (apk) (Entered: 10/24/2022) (0) |
| Oct 24, 2022 | 12 | MOTION for Pro Hac Vice Appearance of Attorney Dennies Varughese, Paul A. Ainsworth, Davin B. Guinn and Robert Stout of Sterne Kessler Goldstein Fox PLLC - filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Palapura, Bindu) (Entered: 10/24/2022) (6) |
| Oct 21, 2022 | 11 | SO ORDERED D.I. 10 . Ordered by Judge Stephanos Bibas on 10/21/2022. (smg) (Entered: 10/21/2022) (0) |
| Oct 20, 2022 | 10 | STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to November 28, 2022 - filed by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Moore, David) (Entered: 10/20/2022) (2) |
| Oct 6, 2022 | 9 | AFFIDAVIT of Service for Summons, Complaint and related papers served on Alembic Pharmaceuticals Limited on October 6, 2022, filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 10/06/2022) (10) |
| Oct 6, 2022 | 8 | SUMMONS Returned Executed by TCD Royalty Sub LP, Galderma Laboratories, L.P..Alembic Pharmaceuticals Inc. served on 10/6/2022, answer due 10/27/2022. (Tigan, Jeremy) (Entered: 10/06/2022) (2) |
| Oct 5, 2022 | 7 | Summons Issued as to Alembic Pharmaceuticals Limited on 10/5/2022. (vfm) (Entered: 10/05/2022) (2) |
| Oct 5, 2022 | 6 | Summons Issued as to Alembic Pharmaceuticals Inc. on 10/5/2022. (vfm) (Entered: 10/05/2022) (2) |
| Oct 5, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Drug Royalty III LP 2, Corporate Parent DRI Healthcare Trust for TCD Royalty Sub LP; Corporate Parent Galderma Services Inc. for Galderma Laboratories, L.P. filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (vfm) (Entered: 10/05/2022) (2) |
| Oct 5, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,749,532 B2 ;8,206,740 B2. (vfm) (Entered: 10/05/2022) (1) |
| Oct 5, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/24/2022. Date of Expiration of Patent: 12/24/2025 (U.S. Patent No. 8,206,740) and 12/19/2027 (U.S. Patent No. 7,749,532).Thirty Month Stay Deadline: 2/24/2025. (vfm) (Entered: 10/05/2022) (1) |
| Oct 5, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 10/05/2022) (3) |
| Oct 5, 2022 | 1 | Complaint* (1) |
